Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 24.10 and a fair value of HKD 29.65 [8][23]. Core Insights - The company achieved a net profit of RMB 244 million in 2025, exceeding expectations, with both major business lines performing well [9][10]. - The company’s revenue for 2025 was RMB 1.058 billion, representing a year-over-year growth of 35.1% [9][10]. - The gross margin improved slightly to 72.1%, benefiting from a higher proportion of high-margin product sales and operational efficiency [9][10]. - The company is expected to launch several new products, including a liquid embolic agent for treating vascular malformations, which is anticipated to be approved in 2026 [10][12]. Financial Forecasts - Revenue projections for 2026 to 2028 are as follows: - 2026: RMB 1.387 billion (31.1% growth) - 2027: RMB 1.808 billion (30.4% growth) - 2028: RMB 2.390 billion (32.2% growth) [3][18]. - Net profit forecasts for the same period are: - 2026: RMB 340 million - 2027: RMB 457 million - 2028: RMB 638 million [3][18]. - The company’s EBITDA is projected to grow significantly, reaching RMB 665 million by 2028 [3]. Business Segments - The neuro-interventional products segment generated RMB 676 million in sales in 2025, a 28% increase year-over-year, driven by new product penetration [9][10]. - The peripheral interventional products segment achieved sales of RMB 379 million, reflecting a 50.3% year-over-year growth, primarily due to rapid market acceptance of new products [9][10]. - The company is focusing on enhancing sales and operational efficiency, with R&D expenses decreasing as a percentage of revenue [10][11]. Market Position and Competitive Advantage - The company is positioned as a leader in the neurovascular and peripheral vascular intervention market, with a comprehensive product line developed over more than a decade [18][19]. - Participation in volume-based procurement has allowed the company to secure significant market share and improve sales volume [20][21]. - The company plans to leverage its partnership with OPTIMED to accelerate overseas market expansion [22].

Core Insights - The neurointervention sector has undergone significant changes since the implementation of centralized procurement in 2021, leading to increased investment interest in domestic medical devices with low localization rates [1][2] - Domestic companies like Guichuang Tongqiao have shown strong performance in centralized procurement, with revenue growth of 31.7% and net profit growth of 76% in the first half of the year [1][2] - The market is characterized by a high proportion of imported brands, with 80% in the neurovascular intervention market and 85% in the peripheral vascular intervention market [1][2] Group 1: Market Dynamics - Centralized procurement has become a critical turning point for the pharmaceutical industry, with some leading companies losing market share while others capitalize on procurement opportunities [2][3] - Guichuang Tongqiao's core business in neurovascular and peripheral vascular intervention products saw sales growth of 25.0% and 46.2% respectively [2][3] - The average price drop for products in centralized procurement ranges from 10% to 25%, with specific products like spring coils seeing a price reduction from 12,000 yuan to a minimum of 3,277 yuan [2][3] Group 2: Future Trends - The trend towards domestic production and the strengthening of leading domestic companies is expected to continue, with improved gross and net profit margins anticipated for companies [3][5] - The National Medical Insurance Administration is optimizing procurement rules, which may lead to more reasonable pricing strategies among companies [3][5] - The volume of neurointervention surgeries is expected to grow, supported by the implementation of DRG 2.0 pricing regulations and the anticipated increase in usage of drug balloons following the upcoming sixth batch of national procurement [4][5] Group 3: Company Performance - Guichuang Tongqiao has set a net profit guidance of 150 million yuan for 2025, having already achieved 120 million yuan in the first half of the year [5] - The company remains confident in exceeding its previous annual profit expectations, despite anticipating higher expenses in the second half of the year [5]

Core Viewpoint - The medical health industry faces significant uncertainties in 2024, yet outstanding companies like Guichuang Tongqiao have emerged successfully, achieving over 100 million yuan in net profit and turning profitable for the first time, demonstrating resilience in a challenging environment [1][24]. Company Performance - Guichuang Tongqiao reported a revenue of 782 million yuan in 2024, a substantial increase of 48.3% year-on-year, with a compound annual growth rate (CAGR) of 64% from 2021 to 2024 [9][12]. - The company achieved a net profit of 100.3 million yuan in 2024, marking its first annual profit, with a significant year-on-year growth of 1,663% when adjusted for non-IFRS measures [12][13]. - The revenue from neurovascular intervention products reached 529 million yuan, accounting for 67.7% of total revenue, with a year-on-year growth of 38.4% [9][12]. - The revenue from peripheral vascular intervention products surged by 74.5% to 252 million yuan, representing 32.3% of total revenue [9][12]. Market Dynamics - The high-value medical consumables market in China has grown from 104.6 billion yuan in 2018 to 156.1 billion yuan in 2023, with vascular intervention being the largest segment at 55.9 billion yuan in 2023, showing a year-on-year growth of 13.77% [4][5]. - The penetration rate of vascular intervention products in China remains low compared to developed countries, indicating significant growth potential in this segment [7][20]. Competitive Landscape - Guichuang Tongqiao has successfully navigated the challenges posed by centralized procurement policies, achieving rapid growth through effective product quality and sales capabilities [15][20]. - The company has participated in multiple rounds of centralized procurement, with 36 out of 47 approved products successfully selected [15][16]. - The competitive landscape is shifting towards a focus on innovation and operational efficiency, with leading players needing to excel in procurement, operational excellence, and continuous innovation [7][24]. International Expansion - Guichuang Tongqiao has expanded its overseas business, generating 22.58 million yuan in 2024, a year-on-year increase of 58.2%, with a CAGR of 87% over the past four years [20][21]. - The company plans to introduce 14 new products in 2025, targeting 11 countries and regions, with expectations of doubling overseas revenue by 2025 [21][22]. Future Outlook - The company is positioned for sustainable growth with a robust product pipeline, having received approvals for over 40 products since 2021, and plans for 17 additional products to be launched between 2025 and 2027 [22][23]. - Guichuang Tongqiao's valuation is expected to recover significantly, with potential inclusion in major stock indices, which could attract substantial capital inflows [25][26].